- Home
- BDN vs ETNB Comparison
BDN vs ETNB Comparison
Compare BDN & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDN
- ETNB
- Stock Information
- Founded
- BDN 1986
- ETNB 2018
- Country
- BDN United States
- ETNB United States
- Employees
- BDN N/A
- ETNB N/A
- Industry
- BDN Real Estate Investment Trusts
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- BDN Real Estate
- ETNB Health Care
- Exchange
- BDN Nasdaq
- ETNB Nasdaq
- Market Cap
- BDN 970.4M
- ETNB 867.4M
- IPO Year
- BDN N/A
- ETNB 2019
- Fundamental
- Price
- BDN $5.88
- ETNB $7.95
- Analyst Decision
- BDN Buy
- ETNB Buy
- Analyst Count
- BDN 3
- ETNB 7
- Target Price
- BDN $5.83
- ETNB $30.33
- AVG Volume (30 Days)
- BDN 1.8M
- ETNB 800.5K
- Earning Date
- BDN 02-04-2025
- ETNB 11-07-2024
- Dividend Yield
- BDN 10.35%
- ETNB N/A
- EPS Growth
- BDN N/A
- ETNB N/A
- EPS
- BDN N/A
- ETNB N/A
- Revenue
- BDN $306,926,000.00
- ETNB N/A
- Revenue This Year
- BDN N/A
- ETNB N/A
- Revenue Next Year
- BDN $2.29
- ETNB N/A
- P/E Ratio
- BDN N/A
- ETNB N/A
- Revenue Growth
- BDN N/A
- ETNB N/A
- 52 Week Low
- BDN $3.85
- ETNB $7.00
- 52 Week High
- BDN $6.54
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- BDN 61.84
- ETNB 44.02
- Support Level
- BDN $5.47
- ETNB $7.44
- Resistance Level
- BDN $5.90
- ETNB $8.09
- Average True Range (ATR)
- BDN 0.18
- ETNB 0.44
- MACD
- BDN 0.02
- ETNB -0.06
- Stochastic Oscillator
- BDN 94.79
- ETNB 22.47
About BDN Brandywine Realty Trust
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).